Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sculier, J.-P.
Right arrow Articles by Ninane, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sculier, J.-P.
Right arrow Articles by Ninane, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:399-409, 2004
© 2004 European Society for Medical Oncology

Original Paper

A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer

Received 28 July 2003; revised 6 October 2003; accepted 19 December 2003

Purpose:

The aim of this study was to determine the role of chemotherapy dose intensity in patients with initially unresectable non-metastatic non-small-cell lung cancer (NSCLC), with survival as primary end point, by testing two different regimens as induction chemotherapy followed by thoracic irradiation.

Patients and methods:

Patients had pathologically proven NSCLC, an initially unresectable non-metastatic tumour without homolateral malignant pleural effusion, no prior history of malignancy and had received no prior therapy. Treatment was randomised for chemotherapy between three courses of MIP (mitomycin C 6 mg/m2; ifosfamide 3g/m2; cisplatin 50 mg/m2) or SuperMIP (mitomycin C 6 mg/m2; ifosfamide 4.5 g/m2; cisplatin 60 mg/m2, carboplatine 200 mg/m2), followed by chest irradiation (60 Gy; five times per week, for 6 weeks). If the tumour became resectable after chemotherapy, surgery was performed, followed by mediastinal irradiation.

Results:

A total of 351 patients were eligible: 176 in the MIP arm and 175 in the SuperMIP arm, with 43% and 51% stages IIIA and IIIB, respectively. There was a significantly higher objective response rate with SuperMIP (46%) compared with MIP (35%) (P = 0.03) [95% confidence interval (CI) for the difference between the response rates, 1% to 22%]. After induction chemotherapy, surgery was performed in 54 (15%) patients (27 per arm) and chest irradiation in 203 (57%) patients (102 in the MIP arm and 101 in the SuperMIP). In terms of survival, there was no statistically significant difference between the two study arms (P = 0.16), with median survival times of, for MIP and SuperMIP, respectively, 12.5 (95% CI 10.1–14.9) and 11.2 (95% CI 9.7–12.8) months. Haematological toxicity and dosage reductions were higher with SuperMIP, which was nevertheless associated with a significantly increased absolute dose intensity.

Conclusions:

High dose-intensity induction chemotherapy does not improve survival in initially unresectable non metastatic NSCLC.

J.-P. Sculier1,*, J.-J. Lafitte3, T. Berghmans1, P. Van Houtte1, J. Lecomte4, J. Thiriaux4, A. Efremidis5, G. Koumakis5, V. Giner6, M. Richez7, J.-L. Corhay8, P. Wackenier9, P. Lothaire1, M. Paesmans1, P. Mommen1 and V. Ninane2,§

1 Institut Jules Bordet, Brussels; 2 CHU Saint-Pierre, Brussels, Belgium; 3 Hôpital Albert Calmette, CHU, Lille, France; 4 CHU de Charleroi, Charleroi, Belgium; 5 Hellenic Cancer Institute, Athens, Greece; 6 Hospital de Sagunto, Valencia, Spain; 7 CHR Saint-Joseph-Warquignies, Boussu; 8 CH Peltzer-La Tourelle, Verviers; 9 Hôpital Ambroise Paré, Mons, Belgium

Key words: chemotherapy, non-small-cell lung cancer, radiotherapy, stage III


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Respir JHome page
J. P. Sculier, J. J. Lafitte, M. Paesmans, J. Lecomte, C. G. Alexopoulos, O. Van Cutsem, V. Giner, A. Efremidis, M. C. Berchier, T. Collon, et al.
Chemotherapy improves low performance status lung cancer patients
Eur. Respir. J., December 1, 2007; 30(6): 1186 - 1192.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Berghmans and J.P. Sculier
Is the Tolerance to MIP Chemotherapy Different Between English and Other European Populations?
J. Clin. Oncol., September 1, 2005; 23(25): 6269 - 6270.
[Full Text] [PDF]

Home page
 JCOHome page
R.M. Rudd, N.H. Gower, S.G. Spiro, S.M. Lee, T.G. Eisen, P.G. Harper, M. Hatton, W.M.C. Martin, and E.M. Rankin
In Reply:
J. Clin. Oncol., September 1, 2005; 23(25): 6270 - 6271.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Thatcher, C. Faivre-Finn, F. Blackhall, H. Anderson, and P. Lorigan
Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 5051s - 5056s.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
T. Berghmans, A. P. Meert, B. Martin, V. Ninane, and J. P. Sculier
Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer
Eur. Respir. J., February 1, 2005; 25(2): 329 - 335.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.